Age Related Macular Degeneration (AMD) Market Facts and Statistics – 2018 Update

Detail Analysis of “Global Age Related Macular Degeneration Market” with respect to region specific market growth and competitive analysis on the basis of major players present in the market. The study also provides a comprehensive review of restraints, market dynamics and drivers. – Outlet till 2023

Pune, India - October 2, 2018 /MarketersMedia/ —

Market Overview:

The global age-related macular degeneration market is estimated to expand at 7.3 % CAGR during the forecast period (2017-2023) owing to the prevalence of diseases among the geriatric population. Age-related macular degeneration (ARMD) is a disease of the retina where the sharp central vision gets blurred. The part of the retina, called macula which allows visualizing fine details is generally affected. A chronic disease that does not cause pain, AMD is majorly observed in patients above the age of 50.

Future Drivers and Restraints Impacting the Market:

The global marker for age-related macular degeneration is anticipated to reach USD 2,200 million by 2023. With the increasing prevalence of disease among the geriatric population, the market for age-related macular degeneration is estimated to propel over the forecast period. For instance, according to the Community Eye Health Journal which was published by London School of Hygiene and Tropical Medicine, around 196 million people are expected to suffer from AMD by 2020. Increasing awareness among the people has also influenced the treatment for AMD globally. Moreover, in third world countries, the emergence of off-patent blockbuster drugs is impacting the market positively. Additionally, growing healthcare expenditure and rising pipeline drugs for AMD are driving the market growth over the assessment period.
On the flipside, high cost of drugs and treatment along with lack of trained ophthalmologists are some of the major restraining factors inhibiting the market growth over the review period. Also, strict mandates and growing off-label use are also hindering the market growth over the years. For instance, a single injection of anti-vascular endothelial growth factor agent for treating AMD costs very high.

Get Exclusive Sample Report @ https://www.marketresearchfuture.com/sample_request/5736

Global Age-Related Macular Degeneration: Market Segmentation

The global market for age-related macular degeneration has been segmented on the basis of route of administration, type, drug, treatment, end-user, and region.
By mode of type, the global market for age-related macular degeneration has been segmented into wet age-related macular degeneration and dry age-related macular degeneration. Among these, the wet age-related macular degeneration is more severe and causes abnormal progression of blood vessels in the damaged macula part which further causes the retinal vison to damage.
By mode of drug, the market has been segmented into Visudyne, Eylea, Avastin, Lucentis, and others.
By route of administration, the market has been segmented into intravitreal, intravenous, and others.
By mode of treatment, the global market for AMD has been segmented into devices, medication, surgery, and others. Among these, the medication segment is sub-segmented into anti-VEGF drugs, blood vessel growth inhibitors, dietary supplements, vitamins, and others. The devices segment has also been sub-segmented into glasses, corrective lenses, contact lenses, and others.
By mode of end-users, the market has been segmented into clinics, diagnostic centers and hospitals, academic research institutes, biotechnology companies and pharmaceuticals, and others.
North America to Hold the Largest Share
Geographically, the market for AMD spans across regions namely North America, Europe, Asia Pacific, and the Middle East & Africa.
North America is predicted to hold the largest market share due to the growing health concern and rising cases of macular degeneration. Around 1.8 million people are suffering from AMD in America and around 7.3 million people are at a significant risk of losing their vision due to AMD, asserts the Centers for Disease Control and Prevention (CDC).
Asia Pacific accounts for more than one-third of the macular generation cases and is expected to grow at a rapid pace than in America and Europe.

Industry News:

Genentech, a member of the Roche Group has announced top line, positive results from the Phase II LADDER study evaluating the safety of its investigational Port Delivery System with ranibizumab in people suffering from wet age-related macular degeneration. The small, refillable eye implant, is slightly longer than a grain of rice, is designed to let people with wet AMD to go several months without needing to visit their ophthalmologist for treatment.

Competitive Analysis:

Some of the key players operating the global market for age-related macular degeneration are Bayer AG, Regeneron Pharmaceutical Inc., Santen Pharmaceuticals, F. Hoffmann-La Roche AG, Novartis AG, and others.

Some Brief Table of Contents of Report:

Chapter 1. Report Prologue

Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation

Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges

TOC Continued...

Do You Have Specific Requirement? Ask to Our Experts @ https://www.marketresearchfuture.com/enquiry/5736

Contact Info:
Name: Nitesh Agrawal
Email: [email protected]
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India
Phone: +1 646 845 9312

Source URL: https://marketersmedia.com/age-related-macular-degeneration-amd-market-facts-and-statistics-2018-update/415703

For more information, please visit https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736

Source: MarketersMedia

Release ID: 415703